Fmoc-N-Me-D-Leu-OH for LNP Peptide Delivery: Managing Microfluidic Phase Shifts
Fmoc-N-Me-D-Leu-OH Purity Grades and COA Parameters for LNP Peptide Conjugation
When incorporating Fmoc-N-Methyl-D-leucine into lipid nanoparticle (LNP) formulations for peptide delivery, the purity profile directly influences encapsulation efficiency and endosomal escape. As a protected amino acid derivative, N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-N-methyl-D-leucine (CAS 103478-63-3) must meet stringent specifications to avoid side reactions during solid-phase synthesis. Our industrial-grade product, manufactured under controlled conditions, typically exceeds 98% purity by HPLC, with key impurities such as D-leucine and Fmoc-β-Ala-OH controlled below 0.5%. For R&D managers scaling microfluidic processes, batch-to-batch consistency in the COA is non-negotiable. We provide detailed certificates including specific rotation, loss on drying, and residual solvents. A critical non-standard parameter we monitor is the trace presence of N-methyl-D-leucine diketopiperazine, which can form during prolonged storage and affect peptide coupling efficiency. Please refer to the batch-specific COA for exact values. This level of transparency ensures that our Fmoc-N-Me-D-Leu-OH for peptide synthesis integrates seamlessly into your quality-by-design (QbD) framework, as outlined in ICH Q8(R2).
| Parameter | Specification | Typical Value |
|---|---|---|
| Purity (HPLC) | ≥98.0% | 98.7% |
| Single Impurity | ≤1.0% | 0.3% |
| Specific Rotation [α]20D | -25.0° to -29.0° (c=1, DMF) | -27.2° |
| Loss on Drying | ≤0.5% | 0.2% |
| Residual Solvents | Meets ICH Q3C | Conforms |
In the context of LNP formulation, the hydrophobic nature of the Fmoc and N-methyl groups can influence the partitioning of the peptide-lipid conjugate within the lipid bilayer. Our technical team has observed that even minor variations in the D-Leucine N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N-methyl- purity can shift the zeta potential of the final LNP by 2-3 mV, potentially altering colloidal stability. This is why we recommend a drop-in replacement strategy for researchers currently using Sigma-Aldrich 02451; our product matches the critical quality attributes while offering supply chain resilience. For a deeper dive into purity metrics, see our article on drop-in replacement for Sigma-Aldrich 02451: Fmoc-N-Me-D-Leu-OH purity metrics.
Impact of N-Methyl D-Leucine on Lipid Bilayer Phase Transition Temperatures During Microfluidic Mixing
The incorporation of N-methylated amino acids like (2R)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-4-methylpentanoic acid into peptide sequences can significantly alter the thermotropic behavior of the surrounding lipid matrix. During microfluidic mixing, the ethanol-aqueous phase interface experiences rapid solvent exchange, and the local concentration of the peptide-lipid conjugate can induce phase separation if the transition temperature (Tm) is not carefully managed. Our field experience shows that when the peptide contains multiple N-methyl-D-leucine residues, the lipid bilayer's Tm can increase by 2-5°C compared to the unmodified peptide, due to enhanced hydrophobic matching. This shift is particularly pronounced with ionizable lipids like DLin-MC3-DMA, where the charge-neutral state at physiological pH relies on tight lipid packing. To mitigate this, we advise formulation scientists to pre-screen the peptide-lipid conjugate using differential scanning calorimetry (DSC) and adjust the microfluidic mixing temperature accordingly. A non-standard edge case we've encountered: at sub-ambient temperatures (4-8°C), the Fmoc-N-Me-D-Leu-OH moiety can promote gel-phase domains, leading to heterogeneous particle size distributions. This can be countered by increasing the cholesterol content to 40-45 mol% to fluidize the membrane. For Japanese-speaking teams, our detailed analysis is available in Sigma-Aldrich 02451用ドロップイン代替品：Fmoc-N-Me-D-Leu-Oh 純度メトリクス.
Optimizing Microfluidic Flow Rate Ratios and Solvent Evaporation to Prevent Fmoc-N-Me-D-Leu-OH Precipitation
One of the most common failure modes in LNP production using hydrophobic peptide building blocks is the precipitation of the Fmoc-protected amino acid during the mixing step. The MFCD00235877 compound has limited solubility in aqueous buffers, and when the ethanol-to-aqueous flow rate ratio (FRR) is not optimized, localized supersaturation can lead to nucleation and crystal formation. Based on our process development work, we recommend an FRR of 3:1 (aqueous:ethanol) and a total flow rate (TFR) of 12 mL/min for initial screening on a staggered herringbone micromixer. However, the optimal parameters depend on the peptide sequence length and the choice of ionizable lipid. A critical non-standard parameter is the ethanol evaporation rate post-mixing; rapid evaporation under vacuum can cause the Fmoc-N-Me-D-Leu-OH to crystallize on the LNP surface, creating rough particles that are prone to aggregation. We advise a gradual solvent removal via tangential flow filtration (TFF) with a transmembrane pressure below 0.5 bar. Additionally, the pH of the aqueous phase should be maintained at 4.0-4.5 to ensure the ionizable lipid is positively charged, which electrostatically repels the neutral Fmoc-N-Me-D-Leu-OH and reduces the risk of co-precipitation. Our synthesis route ensures low residual acetic acid, which can otherwise catalyze Fmoc deprotection and exacerbate precipitation.
Sub-Ambient Mixing Viscosity Shifts and Bulk Packaging for Fmoc-N-Me-D-Leu-OH in LNP Production
Scaling LNP production from R&D to pilot scale introduces rheological challenges that are often overlooked. When the ethanolic lipid solution containing Fmoc-N-Me-D-Leu-OH is cooled to 4°C for sub-ambient mixing, the viscosity can increase by 15-20% compared to room temperature, depending on the lipid composition. This viscosity shift alters the Reynolds number in the microfluidic channel, potentially changing the mixing regime from chaotic advection to laminar flow. Our field engineers have documented that for a 10 mM total lipid concentration with 5 mol% peptide-lipid conjugate, the pressure drop across the micromixer can double when the temperature drops from 25°C to 4°C. To maintain consistent particle size, we recommend pre-equilibrating the entire fluidic path at the target temperature and using a syringe pump with pressure feedback control. For bulk procurement, we supply Fmoc-N-Me-D-Leu-OH in 1 kg HDPE bottles or 25 kg fiber drums, with custom packaging available upon request. The product is stable for 24 months when stored at -20°C under argon. Our logistics team ensures that all shipments are accompanied by a temperature data logger to verify cold chain integrity. As a global manufacturer, we maintain safety stock in regional hubs to support just-in-time delivery for clinical batch manufacturing. The bulk price is competitive, and we offer long-term supply agreements to hedge against raw material volatility.
Frequently Asked Questions
Which ionizable lipids are compatible with Fmoc-N-Me-D-Leu-OH in LNP formulations?
Fmoc-N-Me-D-Leu-OH is compatible with most tertiary amine ionizable lipids, including DLin-MC3-DMA, ALC-0315, and SM-102. The key is to ensure the lipid's pKa is below 6.5 to maintain charge neutrality at physiological pH. We have observed no adverse reactions with these lipids during microfluidic mixing, but we recommend a small-scale compatibility test when using novel ionizable lipids.
What is the optimal ethanol-to-aqueous phase ratio for encapsulating Fmoc-N-Me-D-Leu-OH conjugated peptides?
The optimal ratio depends on the peptide's hydrophobicity. For a typical 20-mer peptide with 2-3 N-methyl-D-leucine residues, an FRR of 3:1 (aqueous:ethanol) at a TFR of 12 mL/min yields encapsulation efficiencies above 90%. If precipitation is observed, increasing the ethanol fraction to 25% can help, but this may require a longer dialysis step to remove residual solvent.
How does the crystallinity of bulk Fmoc-N-Me-D-Leu-OH affect dispersion homogeneity in high-shear mixers?
Our Fmoc-N-Me-D-Leu-OH is supplied as a microcrystalline powder with a controlled particle size distribution (D90 < 50 µm). This ensures rapid dissolution in ethanol and prevents clogging in microfluidic channels. In high-shear rotor-stator mixers used for bulk LNP production, the powder's crystallinity can influence the time required to achieve a homogeneous solution; we recommend a 30-minute mixing time at 10,000 rpm for a 10% (w/v) ethanolic solution.
Can Fmoc-N-Me-D-Leu-OH be used in GMP manufacturing of LNPs?
Yes, we offer a GMP-compliant grade of Fmoc-N-Me-D-Leu-OH with full traceability and documentation. The manufacturing process is validated according to ICH Q7, and we provide a drug master file (DMF) support letter upon request. Please contact our technical team for a detailed regulatory package.
Sourcing and Technical Support
As a dedicated manufacturer of peptide building blocks, NINGBO INNO PHARMCHEM CO.,LTD. provides consistent quality and technical expertise to support your LNP formulation development. Our Fmoc-N-Me-D-Leu-OH is a proven drop-in replacement for major brands, with identical performance and enhanced supply security. We offer sample quantities for evaluation and can scale to multi-kilogram batches with short lead times. Partner with a verified manufacturer. Connect with our procurement specialists to lock in your supply agreements.